SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001720725-22-000071
Filing Date
2022-08-11
Accepted
2022-08-11 16:03:39
Documents
14
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oyst-20220811.htm   iXBRL 8-K 40397
2 EX-99.1 oystearningspressrelease-q.htm EX-99.1 101253
6 GRAPHIC image.jpg GRAPHIC 10267
  Complete submission text file 0001720725-22-000071.txt   312184

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20220811.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20220811_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20220811_pre.xml EX-101.PRE 13045
8 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20220811_htm.xml XML 12156
Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 221155602
SIC: 2836 Biological Products, (No Diagnostic Substances)